Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Fiscal Q1 revenue rose 6% to $339 million, adjusted EPS beat estimates, and management raised revenue, EPS, free-cash-flow, and organic-growth guidance; shares gained 41.1% through August 20.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Expansion ⢠Strong Liquidity ⢠High Leverage HAE shows improving margins, strong cash flow and liquidity, but elevated valuation, high debt, and intangible-asset exposure warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong rebound ⢠Key resistance ⢠Pullback risk Support Level: $106.20â$106.30; stronger support $102.70â$103.10 Resistance Level: $108.80 HAE rebounded strongly over the last month but must break and hold above $108.80 to sustain momentum, while a drop below $106.20 could trigger a pullback toward $102â$103.
Sentiment & News
Key News Insights: ⢠Recurring Revenue ⢠CSL Agreement ⢠MedSurg Growth Haemonetics' recurring plasma revenue, higher-margin MedSurg growth, and CSL agreement support a constructive outlook despite unclear valuation-comparison signals.
AI Summary
HAE is evolving into a higher-quality recurring-revenue medtech platform through CSL-backed plasma consumables and MedSurg expansion, but at ~40x earnings investors should only add on evidence of sustained plasma stability, margin expansion, and vascular-closure adoption, as any execution miss could trigger sharp valuation compression.
Description
Haemonetics Corporation develops and sells medical devices and software for plasma collection, blood center operations, and hospital transfusion and hemostasis management. Its product set includes automated and manual collection systems, donor and blood bank information platforms, and perioperative hemostasis and cell-salvage equipment, marketed through a mix of direct sales, distributors, and representatives. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 20 | Aug 27 | HAE | Haemonetics Corporation | Fiscal Q1 revenue rose 6% to $339 million, adjusted EPS beat estimates, and management raised revenue, EPS, free-cash-flow, and organic-growth guidance; shares gained 41.1% through August 20. | Closed | -3.0% |